Quidel to Hold Second Quarter 2017 Financial Results Conference Call on July 26, 2017
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, will report second quarter 2017 financial results after market close on Wednesday, July 26, 2017.
Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial
officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss
the results and answer questions. During the conference call, the company will also discuss business and financial developments and
trends. The company's statements may contain or constitute material information that has not been previously disclosed.
To participate in the live call by telephone from the U.S., dial 877-930-5791, or from outside the U.S., dial 253-336-7286, and
enter the audience pass code 5565-4364.
A live webcast of the call can be accessed on the Investor Relations section of the Quidel website (http://ir.quidel.com). The website replay will be available for 14 days. The telephone replay will be available
for 48 hours beginning at 8:00 p.m. Eastern Time (5:00 p.m. Pacific Time) on July 26, 2017 by dialing 855-859-2056 from the U.S.,
or by dialing 404-537-3406 for international callers, and entering pass code 5565-4364.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the
Sofia®, QuickVue®, D3® Direct Detection, Thyretain® and InflammaDry® leading brand names, as well as under the new Solana®,
AmpliVue® and Lyra® molecular diagnostic brands, Quidel's products aid in the detection and diagnosis of many critical diseases and
conditions, including, among others, influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's research and development engine is also developing a continuum of diagnostic
solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality
of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive
product portfolio, visit quidel.com.
Quidel Contact:
Quidel Corporation
Randy Steward
Chief Financial Officer
(858) 552-7931
or
Media and Investors Contact:
Quidel Corporation
Ruben Argueta
(858) 646-8023
rargueta@quidel.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170714005559/en/